ArticleJournal of ovarian research2026
Deep spatial transcriptomic profiling of ovarian clear cell carcinoma in the real-world setting.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ovarian clear cell carcinoma (OCCC) is a rare cancer type of significant relevance to East Asian women harboring critical unmet needs for novel therapeutic options. It is a histological subtype of ovarian cancer with distinct pathological features, molecular profiles, and biological functions. Diverse heterogeneity contributing from histopathological and multiomic molecular features has yet to be translated to guide clinical care. Here, we presented a proof-of-concept study to demonstrate the feasibility of applying deep spatial transcriptomic (ST) profiling of tumor samples from an advanced OCCC patient in the real-world setting, aiming to identify therapeutic options beyond standard-of-care. Matched primary ovarian and metastatic bladder tumor sections were profiled by using GeoMx Digital Spatial Profiling and Xenium In Situ platforms. The spatial architecture and neighborhood niches were identified from GeoMx Cancer Transcriptome Atlas (CTA) and Xenium 5K Human Pan Tissue and Pathways Panel. An immunosuppressive Wnt-activating tumor microenvironment (TME) was identified by GeoMx while a tripartite spatial relationship between SLC2A1+ hypoxic cancer cells, IFIT2+ inflammatory cancer cells, and MMP12+ dendritic cells linking towards metabolism and immune responses was identified by Xenium. Our deep ST profiling findings provided significant biological insights and demonstrated feasibility to make novel discoveries, one patient at a time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.